CIPO Patents = 2 (Patent Applications = 1)

EPO Patents = 4 (Patent Applications = 4)

Average Co-Inventor Count = 6.7

ph-index = 4

Forward Citations = 41(Granted Patents)

Location History:

Somerset, NJ (US) (2011 - 2012)
Princeton, NJ (US) (2013 - 2016)

Company Filing History:

4 out of 3,684

Bristol-myers Squibb Compnay

Years Active: 2011-2016

Loading Chart...

5 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 9453039 - Crystal structures of SGLT2 inhibitors and processes for preparing same (2016-09-27),

2. 8501698 - Crystal structures of SGLT2 inhibitors and processes for preparing same (2013-08-06),

3. 8338606 - Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N-((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide (2012-12-25),

4. 8202996 - Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide (2012-06-19),

5. 7919598 - Crystal structures of SGLT2 inhibitors and processes for preparing same (2011-04-05),

Title: The Innovative Journey of Chenchi Wang

Introduction

Chenchi Wang, an accomplished inventor based in Somerset, NJ, has made significant contributions to the field of pharmaceutical sciences. With a robust portfolio of five patents, Wang's work primarily focuses on the development of SGLT2 inhibitors, which play a crucial role in the treatment of diseases such as diabetes. His innovative approach to crystal structures has opened new avenues in drug formulation and delivery.

Latest Patents

Wang's latest patents revolve around the crystal structures of SGLT2 inhibitors and the processes for preparing these structures. His inventions relate specifically to physical crystal structures of compounds characterized by complex formulations. These include pharmaceutical compositions that utilize the structures of compounds I or II, along with methods for treatment of diseases like diabetes. Through his research, he has provided valuable insights into the preparation of these compounds and identified intermediates essential for their synthesis.

Career Highlights

Throughout his career, Chenchi Wang has worked with renowned pharmaceutical companies such as Bristol-Myers Squibb Company and AstraZeneca AB. His tenure at these leading firms has allowed him to collaborate on cutting-edge research and development projects, significantly influencing the pharmaceutical landscape.

Collaborations

Wang has had the opportunity to work alongside notable coworkers such as Jack Z. Gougoutas and Hildegard Lobinger. These collaborations have fostered a collaborative environment, leading to innovative advancements in their field. Together, they have contributed to research that not only enhances our understanding of SGLT2 inhibitors but also improves therapeutic options for patients.

Conclusion

In summary, Chenchi Wang's contributions to the pharmaceutical industry through his innovative patents represent a significant advancement in the treatment of diabetes. His dedication to research and collaboration with esteemed industry professionals underline his status as a key player in developing essential medicinal compounds. Wang's work not only epitomizes innovation but also reflects a commitment to improving health outcomes worldwide.

This text is generated by artificial intelligence and may not be accurate.